https://news.medxy.ai/zh/whole-grain-intake-heart-risk/Medxy AIzh2026-09-23T07:33:04-07:00全谷物摄入与心代谢风险：随机对照试验 Meta 分析证据 https://news.medxy.ai/ja/whole-grain-intake/Medxy AIja2026-09-23T07:32:43-07:00全粒穀物摂取と心血管代謝リスク：ランダム化比較試験のメタ解析からのエビデンス https://news.medxy.ai/vi/whole-grains-heart-risk-2/Medxy AIvi2026-09-23T07:32:14-07:00Ngũ cốc nguyên hạt và nguy cơ tim mạch-chuyển hóa: Bằng chứng từ phân tích tổng hợp các thử nghiệm ngẫu nhiên có đối chứng https://news.medxy.ai/whole-grain-consumption-and-cardiometabolic-risk-evidence-from-meta-analyses-of-randomized-controlled-trials/Medxy AIen2026-09-23T07:31:51-07:00Whole-Grain Consumption and Cardiometabolic Risk: Evidence from Meta-Analyses of Randomized Controlled Trials https://news.medxy.ai/zh/tenecteplase-bleeding-risk/Medxy AIzh2026-09-23T07:21:52-07:00替奈普酶溶栓后脑内出血风险：关键危险因素与临床预警模型 https://news.medxy.ai/ja/intracranial-bleeding-risk/Medxy AIja2026-09-23T07:21:32-07:00急性心筋梗塞におけるテネクテプラーゼ線溶療法後頭蓋内出血の危険因子とその低減戦略 https://news.medxy.ai/vi/hemorrhage-risk-reduction/Medxy AIvi2026-09-23T07:21:10-07:00Nhận diện và giảm thiểu các yếu tố nguy cơ xuất huyết nội sọ sau tiêu sợi huyết bằng tenecteplase trong nhồi máu cơ tim cấp https://news.medxy.ai/identifying-and-mitigating-risk-factors-for-intracranial-haemorrhage-following-tenecteplase-fibrinolysis-in-acute-myocardial-infarction/Medxy AIen2026-09-23T07:20:50-07:00Identifying and Mitigating Risk Factors for Intracranial Haemorrhage Following Tenecteplase Fibrinolysis in Acute Myocardial Infarction https://news.medxy.ai/zh/escc-pd-l1-therapy/Medxy AIzh2026-09-22T07:46:42-07:00解码细胞互作，提升食管鳞状细胞癌新辅助PD-L1阻断疗效 https://news.medxy.ai/ja/pd-l1-therapy-response/Medxy AIja2026-09-22T07:46:26-07:00食道扁平上皮癌における術前PD-L1遮断療法の反応を読み解く細胞間相互作用 https://news.medxy.ai/vi/cell-interaction-pd-l1/Medxy AIvi2026-09-22T07:46:06-07:00Giải mã tương tác tế bào để tăng cường đáp ứng ức chế PD-L1 tân bổ trợ trong ung thư biểu mô tế bào vảy thực quản https://news.medxy.ai/decoding-cellular-interactions-to-enhance-neoadjuvant-pd-l1-blockade-response-in-esophageal-squamous-cell-carcinoma/Medxy AIen2026-09-22T07:45:48-07:00Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma https://news.medxy.ai/zh/carotid-dissection-stroke/Medxy AIzh2026-09-22T07:45:14-07:00颅颈动脉夹层后卒中复发的时间规律与形态学预测因素 https://news.medxy.ai/ja/stroke-recurrence-after-dissection/Medxy AIja2026-09-22T07:44:57-07:00頭蓋頸部動脈解離後の脳卒中再発：時間的推移と画像形態による予測因子 https://news.medxy.ai/vi/stroke-recurrence-prediction-5/Medxy AIvi2026-09-22T07:44:36-07:00Động học theo thời gian và các yếu tố hình thái dự báo tái phát đột quỵ sau bóc tách động mạch sọ-cổ https://news.medxy.ai/temporal-dynamics-and-morphological-predictors-of-stroke-recurrence-after-craniocervical-artery-dissection/Medxy AIen2026-09-22T07:44:16-07:00Temporal Dynamics and Morphological Predictors of Stroke Recurrence After Craniocervical Artery Dissection https://news.medxy.ai/zh/cushing-syndrome-lipid-worsening-2/Medxy AIzh2026-09-22T07:43:42-07:00库欣综合征术后早期血脂反常恶化：对心血管风险管理的启示 https://news.medxy.ai/ja/cushing-syndrome-lipid-worsening/Medxy AIja2026-09-22T07:43:25-07:00クッシング症候群の術後早期にみられる脂質悪化：心血管リスク評価と管理への示唆 https://news.medxy.ai/vi/cushing-syndrome-lipids/Medxy AIvi2026-09-22T07:43:05-07:00Hội chứng Cushing: Rối loạn lipid có thể nặng hơn sớm sau mổ và hàm ý nguy cơ tim mạch https://news.medxy.ai/early-lipid-deterioration/Medxy AIen2026-09-22T07:42:46-07:00Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and Management https://news.medxy.ai/ja/gene-editing-cvd/Medxy AIja2026-09-22T07:42:12-07:00心血管疾患における遺伝子編集療法：2026年ACC声明の重要ポイント https://news.medxy.ai/vi/76924-2/Medxy AIvi2026-09-22T07:41:38-07:00Các liệu pháp chỉnh sửa gen cho bệnh tim mạch: Những điểm chính từ Tuyên bố Khoa học năm 2026 của ACC https://news.medxy.ai/zh/cardiovascular-gene-editing/Medxy AIzh2026-09-22T07:41:02-07:00心血管疾病基因编辑治疗：2026 年 ACC 科学声明要点解读 https://news.medxy.ai/gene-editing-therapy-in-cardiovascular-disease-key-takeaways-from-the-2026-acc-scientific-statement/Medxy AIen2026-09-22T07:40:28-07:00Gene Editing Therapy in Cardiovascular Disease: Key Takeaways from the 2026 ACC Scientific Statement https://news.medxy.ai/zh/veteran-intimate-partner-violence/Medxy AIzh2026-09-22T07:34:45-07:00破解退伍军人亲密伴侣暴力医法合作落地难题：来自VA的启示 https://news.medxy.ai/ja/intimate-partner-violence/Medxy AIja2026-09-22T07:34:27-07:00親密なパートナー間暴力を経験する退役軍人への医療-法的連携を阻む壁を越えて：VAからの示唆 https://news.medxy.ai/vi/76913-2/Medxy AIvi2026-09-22T07:34:06-07:00Các vấn đề y tế liên quan đến bạo lực từ bạn tình ở cựu chiến binh https://news.medxy.ai/overcoming-barriers-to-medical-legal-partnerships-for-veterans-experiencing-intimate-partner-violence-insights-from-the-va/Medxy AIen2026-09-22T07:33:45-07:00Overcoming Barriers to Medical-Legal Partnerships for Veterans Experiencing Intimate Partner Violence: Insights from the VA https://news.medxy.ai/zh/dapirolizumab-sle-study/Medxy AIzh2026-09-22T05:41:33-07:00Dapirolizumab Pegol 改善系统性红斑狼疮疾病活动度：来自 PHOENYCS GO Ⅲ期试验及既往研究的证据 https://news.medxy.ai/ja/76203-2/Medxy AIja2026-09-22T05:41:05-07:00ダピロリズマブ・ペゴルによる全身性エリテマトーデスの疾患活動性の改善：PHOENYCS GO第III相試験および過去の研究からのエビデンス https://news.medxy.ai/vi/dapirolizumab-lupus/Medxy AIvi2026-09-22T05:40:27-07:00Dapirolizumab Pegol cải thiện hoạt tính bệnh ở lupus ban đỏ hệ thống: bằng chứng từ thử nghiệm pha 3 PHOENYCS GO và các nghiên cứu trước đó https://news.medxy.ai/dapirolizumab-pegol-improves-disease-activity-in-systemic-lupus-erythematosus-evidence-from-phase-3-phoenycs-go-trial-and-prior-studies/Medxy AIen2026-09-22T05:39:58-07:00Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies https://news.medxy.ai/zh/gvhd-prevention-evolution/Medxy AIzh2026-09-22T05:36:55-07:00alloHSCT中GVHD预防的演变：来自西班牙大型真实世界队列的启示 https://news.medxy.ai/ja/gvhd-prevention-evolution-2/Medxy AIja2026-09-22T05:36:33-07:00同種造血幹細胞移植におけるGVHD予防の進化：スペイン大規模実臨床コホートからの示唆 https://news.medxy.ai/vi/gvhd-prophylaxis-allohsct/Medxy AIvi2026-09-22T05:36:09-07:00Dự phòng GVHD trong alloHSCT đang thay đổi: Góc nhìn từ một đoàn hệ thực tế quy mô lớn tại Tây Ban Nha https://news.medxy.ai/evolving-gvhd-prophylaxis-in-allohsct-insights-from-a-large-real-world-spanish-cohort/Medxy AIen2026-09-22T05:35:47-07:00Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort https://news.medxy.ai/zh/car-t-lymphoma-risks/Medxy AIzh2026-09-22T05:35:05-07:00揭示隐藏风险：CAR T细胞治疗后T细胞淋巴瘤——罕见但真实存在的隐忧 https://news.medxy.ai/ja/car-t-therapy-risks/Medxy AIja2026-09-22T05:34:43-07:00CAR T細胞療法後に潜む稀なリスク――T細胞リンパ腫を読み解く https://news.medxy.ai/vi/car-t-cell-therapy-risks/Medxy AIvi2026-09-22T05:34:18-07:00Hiểu rõ nguy cơ: U lympho tế bào T sau liệu pháp CAR T-cell therapy — mối lo hiếm gặp nhưng có thật https://news.medxy.ai/t-cell-lymphoma-risks/Medxy AIen2026-09-22T05:33:53-07:00Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern https://news.medxy.ai/zh/real-world-evidence-myeloma/Medxy AIzh2026-09-22T05:33:04-07:00全球真实世界证据：多发性骨髓瘤自体干细胞移植后维持治疗可带来生存获益 https://news.medxy.ai/ja/76183-2/Medxy AIja2026-09-22T05:32:42-07:00多発性骨髄腫における自家幹細胞移植後の維持療法は、生存上の利益をもたらす可能性がある https://news.medxy.ai/vi/stem-cell-transplant-survival/Medxy AIvi2026-09-22T05:32:20-07:00Bằng chứng thực tế toàn cầu cho thấy điều trị duy trì sau ghép tế bào gốc tự thân cải thiện sống còn ở đa u tủy https://news.medxy.ai/global-real-world-evidence-shows-survival-benefit-of-maintenance-therapy-post-autologous-stem-cell-transplant-in-multiple-myeloma/Medxy AIen2026-09-22T05:31:58-07:00Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma https://news.medxy.ai/zh/ai-fibrosis-diagnosis/Medxy AIzh2026-09-22T05:29:36-07:00AI赋能骨髓纤维化诊断：Continuous Indexing of Fibrosis（CIF）的临床评估 https://news.medxy.ai/ja/ai-fibrosis-diagnosis-2/Medxy AIja2026-09-22T05:29:15-07:00骨髄線維化診断を高精度化：AI駆動型Continuous Indexing of Fibrosis（CIF）の臨床評価 https://news.medxy.ai/vi/bone-marrow-fibrosis-diagnosis/Medxy AIvi2026-09-22T05:28:52-07:00Nâng cao chẩn đoán xơ hóa tủy xương: Đánh giá lâm sàng chỉ số liên tục xơ hóa do AI hỗ trợ (CIF) https://news.medxy.ai/enhancing-bone-marrow-fibrosis-diagnosis-clinical-evaluation-of-ai-driven-continuous-indexing-of-fibrosis-cif/Medxy AIen2026-09-22T05:28:26-07:00Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF) https://news.medxy.ai/zh/76169-2/Medxy AIzh2026-09-22T05:27:46-07:00靶向IL-17A驱动的PTGS2/NLRP3炎性小体活性：针对PTPN11突变型JMML的新治疗策略 https://news.medxy.ai/ja/il-17a-ptgs2-nlrp3-targeting/Medxy AIja2026-09-22T05:27:21-07:00IL-17A駆動のPTGS2/NLRP3インフラマソーム活性を標的化：PTPN11変異JMMLに対する新たな治療戦略 https://news.medxy.ai/vi/il-17a-ptpn11-treatment/Medxy AIvi2026-09-22T05:26:53-07:00Nhắm trúng trục IL-17A thúc đẩy hoạt hóa PTGS2/NLRP3: hướng điều trị mới trong JMML đột biến PTPN11 https://news.medxy.ai/targeting-il-17a-driven-ptgs2-nlrp3-inflammasome-activation-a-novel-therapeutic-approach-in-ptpn11-mutant-juvenile-myelomonocytic-leukemia/Medxy AIen2026-09-22T05:26:27-07:00Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia https://news.medxy.ai/zh/target-pkmyt1/Medxy AIzh2026-09-22T05:25:36-07:00靶向PKMYT1：高危del(17p)多发性骨髓瘤的潜在治疗新策略 https://news.medxy.ai/ja/pkmyt1-targeting/Medxy AIja2026-09-22T05:25:16-07:00PKMYT1を標的にする：del(17p)高リスク多発性骨髄腫に対する有望な治療戦略 https://news.medxy.ai/vi/target-pkmyt1-2/Medxy AIvi2026-09-22T05:24:52-07:00Nhắm vào PKMYT1: Chiến lược điều trị đầy hứa hẹn cho đa u tủy nguy cơ cao del(17p) https://news.medxy.ai/targeting-pkmyt1-a-promising-therapeutic-strategy-for-high-risk-del17p-multiple-myeloma/Medxy AIen2026-09-22T05:24:29-07:00Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma https://news.medxy.ai/zh/ibrutinib-venetoclax-lymphoma/Medxy AIzh2026-09-22T05:23:40-07:00老年及TP53突变非母细胞样套细胞淋巴瘤的一线伊布替尼联合维奈克拉：疗效与安全性 https://news.medxy.ai/ja/ibrutinib-benetoclax-treatment/Medxy AIja2026-09-22T05:23:18-07:00非芽球様マントル細胞リンパ腫に対するイブルチニブ＋ベネトクラクス一次治療：高齢者およびTP53変異例における有効性と安全性 https://news.medxy.ai/vi/ibrutinib-venetoclax-lymphoma-2/Medxy AIvi2026-09-22T05:22:53-07:00Ibrutinib phối hợp Venetoclax ở tuyến đầu cho u lympho tế bào áo thể không blastoid: Hiệu quả và độ an toàn ở người cao tuổi và bệnh nhân mang đột biến TP53 https://news.medxy.ai/first-line-ibrutinib-plus-venetoclax-in-nonblastoid-mantle-cell-lymphoma-efficacy-and-safety-in-older-adults-and-tp53-mutant-patients/Medxy AIen2026-09-22T05:22:28-07:00First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients https://news.medxy.ai/zh/lung-transplant-kidney-impact/Medxy AIzh2026-09-22T05:21:40-07:002023年安全网政策对肺移植后肾移植的影响：移植实践与结局的早期变化 https://news.medxy.ai/ja/safety-net-impact-transplant/Medxy AIja2026-09-22T05:21:21-07:002023年safety net policyが肺移植後腎移植に与えた影響：移植診療と転帰の早期変化 https://news.medxy.ai/vi/safety-net-impact/Medxy AIvi2026-09-22T05:20:57-07:00Tác động của chính sách “safety net” năm 2023 đối với ghép thận sau ghép phổi: Những thay đổi sớm trong thực hành ghép và kết cục https://news.medxy.ai/impact-of-the-2023-safety-net-policy-on-kidney-after-lung-transplantation-early-changes-in-transplant-practices-and-outcomes/Medxy AIen2026-09-22T05:20:32-07:00Impact of the 2023 Safety Net Policy on Kidney After Lung Transplantation: Early Changes in Transplant Practices and Outcomes https://news.medxy.ai/zh/dupilumab-asthma-effects/Medxy AIzh2026-09-22T05:19:46-07:00CT视角下度普利尤单抗对中重度哮喘黏液栓动态及放射密度的影响 https://news.medxy.ai/ja/mucus-plug-dupilumab-effects/Medxy AIja2026-09-22T05:19:24-07:00中等症から重症喘息における粘液栓の変化と放射線濃度へのデュピルマブの影響：CT画像からみた解析 https://news.medxy.ai/vi/dupilumab-asthma-ct-2/Medxy AIvi2026-09-22T05:19:02-07:00Tác động của Dupilumab lên động học nút nhầy và mật độ tia X trong hen phế quản mức độ trung bình đến nặng: góc nhìn từ chẩn đoán hình ảnh CT https://news.medxy.ai/dupilumab-asthma-ct/Medxy AIen2026-09-22T05:18:37-07:00Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective https://news.medxy.ai/zh/lung-cancer-screening-quality/Medxy AIzh2026-09-22T05:17:52-07:00远程医疗与面对面沟通下肺癌筛查共享决策质量：患者感知、证据综述与临床启示 https://news.medxy.ai/ja/76143-2/Medxy AIja2026-09-22T05:17:31-07:00遠隔医療と対面診療における肺がん検診の共有意思決定の質 https://news.medxy.ai/vi/patient-awareness-shared-decision-making/Medxy AIvi2026-09-22T05:17:02-07:00Nhận thức của bệnh nhân về chất lượng ra quyết định chung trong tầm soát ung thư phổi: so sánh giữa tư vấn từ xa và trao đổi trực tiếp, tổng hợp bằng chứng và góc nhìn lâm sàng https://news.medxy.ai/patient-perceptions-of-quality-of-shared-decision-making-for-lung-cancer-screening-in-telehealth-vs-in-person-discussions-a-synthesis-of-evidence-and-clinical-insights/Medxy AIen2026-09-22T05:16:37-07:00Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights https://news.medxy.ai/zh/bridging-eye-care-gap/Medxy AIzh2026-09-22T05:15:37-07:00弥合视力照护鸿沟：基于 CFIR 的美国社区成人眼筛查研究启示 https://news.medxy.ai/ja/ophthalmology-screening-challenges/Medxy AIja2026-09-22T05:15:14-07:00地域眼科スクリーニングの課題をどう越えるか：米国のCFIRガイド研究が示す示唆 https://news.medxy.ai/vi/eye-care-gap/Medxy AIvi2026-09-22T05:14:42-07:00Thu hẹp khoảng cách trong chăm sóc thị lực: Những phát hiện từ nghiên cứu định hướng CFIR về sàng lọc mắt cho người lớn dựa vào cộng đồng tại Hoa Kỳ https://news.medxy.ai/bridging-the-gap-in-vision-care-insights-from-a-cfir-guided-study-on-community-based-adult-eye-screening-in-the-u-s/Medxy AIen2026-09-22T05:14:16-07:00Bridging the Gap in Vision Care: Insights from a CFIR-Guided Study on Community-Based Adult Eye Screening in the U.S. https://news.medxy.ai/zh/76134-2/Medxy AIzh2026-09-22T05:13:30-07:00眼睑下垂综合征（Sagging Eye Syndrome）术后上斜视复发的研究 https://news.medxy.ai/ja/sagging-eye-syndrome/Medxy AIja2026-09-22T05:13:07-07:00Sagging Eye Syndromeにおける術後hypertropia再発の長期経過：知見と臨床的含意 https://news.medxy.ai/vi/76132-2/Medxy AIvi2026-09-22T05:12:41-07:00Diễn tiến dài hạn của tình trạng tái phát lác đứng lên (hypertropia) sau phẫu thuật ở bệnh nhân mắc hội chứng mắt xệ (Sagging Eye Syndrome) https://news.medxy.ai/long-term-recurrence-of-hypertropia-after-surgery-in-sagging-eye-syndrome-insights-and-implications/Medxy AIen2026-09-22T05:12:15-07:00Long-Term Recurrence of Hypertropia After Surgery in Sagging Eye Syndrome: Insights and Implications https://news.medxy.ai/zh/76129-2/Medxy AIzh2026-09-22T05:11:28-07:00超广角OCT揭示了伴有后巩膜葡萄肿的病理性近视中中央凹陷的形态及视神经乳头的特征 https://news.medxy.ai/ja/76128-2/Medxy AIja2026-09-22T05:11:04-07:00広範囲UWF-OCTが明らかにする、後部強膜ブリージアを伴う病的近視における黄斑部および視神経乳頭の形態的特徴 https://news.medxy.ai/vi/uwf-oct-central-nerve/Medxy AIvi2026-09-22T05:10:38-07:00UWF-OCT trường siêu rộng hé lộ địa hình hố trung tâm và đầu dây thần kinh thị giác khác biệt trong cận thị bệnh lý kèm phình lồi củng mạc sau https://news.medxy.ai/ultra-widefield-oct-reveals-distinct-foveal-and-optic-nerve-head-topography-in-pathologic-myopia-with-posterior-staphyloma/Medxy AIen2026-09-22T05:10:13-07:00Ultra-Widefield OCT Reveals Distinct Foveal and Optic Nerve Head Topography in Pathologic Myopia with Posterior Staphyloma https://news.medxy.ai/zh/pcv-treatment-outcomes/Medxy AIzh2026-09-22T05:09:27-07:00PCV完全消退后按需阿柏西普治疗的结局：临床综述 https://news.medxy.ai/ja/aflibercept-treatment-outcomes/Medxy AIja2026-09-22T05:09:02-07:00ポリープ状脈絡膜血管症における完全退縮後の必要時アフリベルセプト治療の転帰：臨床レビュー https://news.medxy.ai/vi/76122-2/Medxy AIvi2026-09-22T05:08:34-07:00Kết quả điều trị bằng aflibercept theo nhu cầu sau khi bệnh lý mạch hắc mạc đa giác (PCV) đã thoái lui hoàn toàn https://news.medxy.ai/outcomes-of-as-needed-aflibercept-treatment-after-complete-regression-in-polypoidal-choroidal-vasculopathy-a-clinical-review/Medxy AIen2026-09-22T05:08:02-07:00Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review https://news.medxy.ai/zh/76119-2/Medxy AIzh2026-09-22T05:07:08-07:00舒马曲坦（Susetiridine）能减少头颈部手术后阿片类药物使用 https://news.medxy.ai/ja/suzoterijin-opioid-use/Medxy AIja2026-09-22T05:06:48-07:00頭頸部手術後のオピオイド使用を抑えるスゼトリジンの役割：後ろ向きコホート解析 https://news.medxy.ai/vi/opioid-reduction-surgery/Medxy AIvi2026-09-22T05:06:25-07:00Suzetrigine giúp giảm sử dụng opioid sau phẫu thuật đầu cổ như thế nào? Phân tích đoàn hệ hồi cứu https://news.medxy.ai/suzetrigines-role-in-reducing-opioid-use-after-head-and-neck-surgery-a-retrospective-cohort-analysis/Medxy AIen2026-09-22T05:06:03-07:00Suzetrigine’s Role in Reducing Opioid Use After Head and Neck Surgery: A Retrospective Cohort Analysis https://news.medxy.ai/zh/rf-ablation-thyroid-nodules/Medxy AIzh2026-09-22T05:05:19-07:00射频消融：甲状腺叶切除术后甲状腺结节的微创替代方案 https://news.medxy.ai/ja/radiofrequency-ablation-options/Medxy AIja2026-09-22T05:05:00-07:00葉切除後の甲状腺結節に対する低侵襲選択肢：Radiofrequency Ablationの有用性 https://news.medxy.ai/vi/radiofrequency-ablation/Medxy AIvi2026-09-22T05:04:38-07:00Đốt sóng cao tần: Lựa chọn ít xâm lấn cho nhân giáp sau cắt thùy giáp https://news.medxy.ai/radiofrequency-ablation-a-minimally-invasive-alternative-for-thyroid-nodules-post-lobectomy/Medxy AIen2026-09-22T05:04:18-07:00Radiofrequency Ablation: A Minimally Invasive Alternative for Thyroid Nodules Post-Lobectomy https://news.medxy.ai/zh/cvemp-vhit-discrepancy/Medxy AIzh2026-09-22T05:03:37-07:00cVEMP与后半规管vHIT为何常不一致：1770只耳研究揭示前庭诊断新视角 https://news.medxy.ai/ja/vemp-vhit-comparison/Medxy AIja2026-09-22T05:03:13-07:00頸部VEMPと後半規管vHITは本当に同じ機能を見ているのか？―1770耳の解析から見えた前庭診断の新たな示唆 https://news.medxy.ai/vi/cvemp-vhit-difference/Medxy AIvi2026-09-22T05:02:48-07:00Sự phân ly chức năng giữa cVEMP cổ và vHIT ống bán khuyên sau: gợi ý mới cho chẩn đoán tiền đình trên 1770 tai không chọn lọc https://news.medxy.ai/functional-dissociation-of-cervical-vemp-and-posterior-canal-vhit-implications-for-vestibular-diagnostics-in-1770-unselected-ears/Medxy AIen2026-09-22T05:02:24-07:00Functional Dissociation of Cervical VEMP and Posterior Canal vHIT: Implications for Vestibular Diagnostics in 1770 Unselected Ears https://news.medxy.ai/zh/thyroid-compression-symptoms-2/Medxy AIzh2026-09-22T05:01:37-07:00甲状腺压迫性症状：优化诊断与治疗以改善预后 https://news.medxy.ai/ja/76103-2/Medxy AIja2026-09-22T05:01:16-07:00甲状腺による圧迫症状：予後改善に向けた診断と治療の最適化 https://news.medxy.ai/vi/thyroid-compression-symptoms/Medxy AIvi2026-09-22T05:00:51-07:00Triệu chứng chèn ép do tuyến giáp: Tối ưu hóa chẩn đoán và điều trị để cải thiện kết cục https://news.medxy.ai/thyroid-compressive-symptoms-optimizing-diagnosis-and-management-for-improved-outcomes/Medxy AIen2026-09-22T05:00:25-07:00Thyroid Compressive Symptoms: Optimizing Diagnosis and Management for Improved Outcomes